Detalles de la búsqueda
1.
Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization.
Am Heart J
; 188: 156-166, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28577671
2.
Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome.
Clin Chem
; 63(7): 1214-1226, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28515099
3.
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.
Eur Heart J
; 37(4): 412-22, 2016 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-26637834
4.
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement.
Circulation
; 131(1): 62-73, 2015 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-25400062
5.
Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial.
Stroke
; 47(4): 1135-9, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26883498
6.
Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Pediatr Blood Cancer
; 63(2): 299-305, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26402148
7.
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
N Engl J Med
; 367(14): 1297-309, 2012 Oct 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-22920930
8.
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
Am Heart J
; 170(4): 683-694.e3, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26386792
9.
Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.
J Pediatr Hematol Oncol
; 37(1): 1-9, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25493452
10.
The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Platelets
; 26(5): 474-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25140584
11.
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Circulation
; 128(8): 823-33, 2013 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23852610
12.
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
Lancet
; 382(9892): 605-13, 2013 Aug 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-23953385
13.
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.
J Thromb Thrombolysis
; 38(2): 127-36, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24043374
14.
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.
Br J Clin Pharmacol
; 75(6): 1433-44, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23171128
15.
A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
Platelets
; 24(1): 15-25, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-22372531
16.
Rationale and design of the TAXUS Liberte Post-Approval Study: examination of patients receiving the TAXUS Liberté stent with concomitant prasugrel therapy in routine interventional cardiology practice.
Am Heart J
; 163(2): 142-8.e6, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22305829
17.
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
Br J Clin Pharmacol
; 73(1): 93-105, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21689142
18.
Response to letters regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement".
Circulation
; 132(13): e166-7, 2015 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-26416639
19.
The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
J Cardiovasc Pharmacol
; 57(3): 317-24, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21266916
20.
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
J Cardiovasc Pharmacol
; 56(1): 29-37, 2010 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-20386460